

Alessandra Maciel Almeida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7247282/publications.pdf>

Version: 2024-02-01

27
papers

274
citations

1040056

9
h-index

996975

15
g-index

30
all docs

30
docs citations

30
times ranked

460
citing authors

#	ARTICLE	IF	CITATIONS
1	Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 473-479.	1.4	4
2	The increasing burden of pancreatic cancer in Brazil from 2000 to 2019: estimates from the Global Burden of Disease Study 2019.. Revista Da Sociedade Brasileira De Medicina Tropical, 2022, 55, e0271.	0.9	3
3	Functionality assessment in patients with rheumatic diseases undergoing treatment in the Public Health System. Einstein (Sao Paulo, Brazil), 2022, 20, eAO6453.	0.7	0
4	Biological therapy in psoriatic arthritis patients with and without previous biologic experience. Medicina, 2022, 55, .	0.1	0
5	A cross-sectional study of the quality of life of patients living with type 1 diabetes treated with insulin glargine and neutral protamine Hagedorn insulin and the implications. Journal of Pharmaceutical Health Services Research, 2021, 12, 332-342.	0.6	3
6	Influence of pharmaceutical services organization on the availability of essential medicines in a public health system. Journal of Comparative Effectiveness Research, 2021, 10, 519-532.	1.4	4
7	Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study. Pharmacy Practice, 2021, 19, 2312.	1.5	5
8	Health-Related Quality of Life in Psoriatic Arthritis: Findings and Implications. Value in Health Regional Issues, 2021, 26, 135-141.	1.2	8
9	Sexual function and metabolic/hormonal changes in women using long-term hormonal and non-hormonal contraceptives: a pilot study. BMC Women's Health, 2020, 20, 240.	2.0	7
10	Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 21, 1-6.	1.4	4
11	FIRST LINE OF SUBCUTANEOUS ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS: A PROSPECTIVE COHORT STUDY. Expert Review of Clinical Immunology, 2020, 16, 1217-1225.	3.0	2
12	Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff. Hospital Practice (1995), 2020, 48, 213-222.	1.0	5
13	The use of probiotics as a supplementary therapy in the treatment of patients with asthma: a pilot study and implications. Clinics, 2019, 74, e950.	1.5	9
14	Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations. Expert Review of Clinical Immunology, 2019, 15, 879-887.	3.0	14
15	Medication persistence for psoriatic arthritis in a Brazilian real-world setting. Future Science OA, 2019, 5, FSO369.	1.9	13
16	First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. Expert Review of Clinical Pharmacology, 2019, 12, 363-370.	3.1	9
17	Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study. BMJ Open, 2019, 9, e027059.	1.9	10
18	Access to high-cost medications for psoriatic arthritis in the National Health System in Brazil: the long path up to dispensation. Advances in Rheumatology, 2019, 59, 48.	1.7	11

#	ARTICLE	IF	CITATIONS
19	Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy Implications. Patient, 2018, 11, 377-389.	2.7	37
20	Effectiveness and safety of anti-TNF in psoriatic arthritis patients in Brazil: a post-incorporation analysis. Journal of Comparative Effectiveness Research, 2018, 7, 989-1000.	1.4	10
21	Access to medicines by patients of the primary health care in the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 20s.	1.7	25
22	Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. Expert Review of Clinical Pharmacology, 2016, 9, 991-999.	3.1	15
23	Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. Journal of Comparative Effectiveness Research, 2016, 5, 539-549.	1.4	13
24	Budget impact analysis of medicines: updated systematic review and implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 257-266.	1.4	31
25	Poorer functionality is related to better quality of life response following the use of biological drugs: 6-month outcomes in a prospective cohort from the Public Health System (Sistema Único de Saúde) in Brazil. BMC Medical Research Methodology, 2015, 15, 403-412.	1.4	11
26	Chronic Hepatitis B Treatment: The Cost-Effectiveness of Interferon Compared to Lamivudine. Value in Health, 2011, 14, S24-S28.	0.3	5
27	A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications. Clinical Diabetes, 2010, 28, 1-10.	2.2	0